- Coeptis Therapeutics Holdings (COEP, Financial) has filed a Form S-4 registration statement with the SEC for a proposed merger with Z Squared Inc.
- The registration statement includes a preliminary proxy statement/prospectus for the transaction.
- The merger is pending as the registration statement has yet to become effective and information may change.
Coeptis Therapeutics Holdings, Inc. (COEP), a technology and biopharmaceutical company, announced that it has filed a registration statement on Form S-4 with the Securities and Exchange Commission (SEC). This filing is in relation to its previously announced proposed merger with Z Squared Inc.
The Form S-4 includes a preliminary proxy statement and prospectus concerning the proposed transaction. It should be noted that the registration statement is currently under review and has not become effective. Consequently, the disclosed information is subject to change.
Coeptis, headquartered in Wexford, Pennsylvania, focuses on innovative cell therapy platforms for cancer, autoimmune, and infectious diseases. This merger aligns with Coeptis' goals of enhancing treatment paradigms and improving patient outcomes through advanced biopharmaceutical solutions.
Z Squared, on the other hand, is concentrated on digital asset compute mining, primarily generating Dogecoin (DOGE) and other altcoins, thus providing investors with exposure to the rapidly expanding altcoin market.
Investors and stakeholders are encouraged to review the preliminary proxy statement/information statement/prospectus, which will be mailed once the registration statement is declared effective by the SEC. For further details, documents will be accessible free of charge on the SEC's website.
